Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

RNAing toward a new therapy for hemophilia

Bhavya S. Doshi, Robert F. Sidonio, Jr

Blood (2024) 143 (22): 2219–2221.

https://doi.org/10.1182/blood.2024024295

Published: 2024

Journal Articles

Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module

Nicholas A. Arce, Zoe Markham-Lee, Qian Liang, Shabir Najmudin, Emily R. Legan, Gabrielle Dean, Ally J. Su, Moriah S. Wilson, Robert F. Sidonio, Pete Lollar, Jonas Emsley, Renhao Li

Blood (2024) 143 (19): 1992–2004.

https://doi.org/10.1182/blood.2023022038

Published: 2024

Includes: Supplemental data

Journal Articles

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Robert Klamroth, Robert F Sidonio, Jr., Yesim Dargaud, Víctor Jiménez-Yuste, Rolf Ljung, Guy Young, Pratima Chowdary

Blood (2023) 142 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2023-181725

Published: 2023

Journal Articles

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study

Robert F Sidonio, Jr., Leonid Dubey, Kateryna V Vilchevska, Adlette Inati, Claudia Djambas Khayat

Blood (2023) 142 (Supplement 1): 3992.

https://doi.org/10.1182/blood-2023-180513

Published: 2023

Journal Articles

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Heavy Menstrual Bleeding in Females with Von Willebrand Disease

Csongor Kiss, Zoltan Boda, Claudia Djambas Khayat, Leonid Dubey, Robert F Sidonio, Jr.

Blood (2023) 142 (Supplement 1): 3997.

https://doi.org/10.1182/blood-2023-180498

Published: 2023

Journal Articles

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease

Ana Boban, Robert F Sidonio, Jr., Leonid Dubey, Kateryna V Vilchevska, Adlette Inati, Claudia Djambas Khayat

Blood (2023) 142 (Supplement 1): 5509.

https://doi.org/10.1182/blood-2023-180029

Published: 2023

Journal Articles

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD

Robert F. Sidonio, Angela C Weyand, Tammuella Chrisentery-Singleton, Martin Chandler, Haduwa Momoh, Priscilla Driscoll-Shempp, Bethany Jones, Natalia Nieto, Jorge Caicedo

Blood (2023) 142 (Supplement 1): 2613.

https://doi.org/10.1182/blood-2023-174729

Published: 2023

Journal Articles

Immunogenicity of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate during the Wil-31 Prophylaxis Study in Patients with Von Willebrand Disease

Claudia Djambas Khayat, Robert F Sidonio, Jr., Anna Pavlova

Blood (2023) 142 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2023-180585

Published: 2023

Journal Articles

Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate

Kateryna V Vilchevska, Vladimir Vdovin, Margarita Timofeeva, Claudia Djambas Khayat, Adlette Inati, Robert F Sidonio, Jr.

Blood (2023) 142 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2023-180526

Published: 2023

Journal Articles

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Shannon L Carpenter, Martin Chandler, Michael F Guerrera, Lynn Malec, Matthew Manuel, Michael Recht, Ulrike Reiss, Robert F. Sidonio, Jr., Cristina Tarango, Marijke Van den Berg, Michael Wang, Courtney D. Thornburg

Blood (2022) 140 (Supplement 1): 63–64.

https://doi.org/10.1182/blood-2022-162660

Published: 2022

Journal Articles

Assessment of Menstrual Health and Bleeding Symptoms in Adolescent Girls and Young Women with Sickle Cell Disease

Brittany Notice, Elizabeth Soffer, Yijin Xiang, Kelly Tickle, Beatrice E Gee, Robert F. Sidonio, Jr., Glaivy Batsuli

Blood (2022) 140 (Supplement 1): 5116–5118.

https://doi.org/10.1182/blood-2022-167857

Published: 2022

Journal Articles

Performance of the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH) 2.0

Marquita Decker-Palmer, Susan Mathias, Hilary Colwell, Ross Crosby, Brittany Gentile, Janet Chupka, Robert F. Sidonio, Jr., Michael Recht, Amy D. Shapiro, James Zazzali

Blood (2022) 140 (Supplement 1): 11328–11329.

https://doi.org/10.1182/blood-2022-157932

Published: 2022

Journal Articles

Clinical Characteristics Impacting Health-Related Quality of Life in Persons with Von Willebrand Disease

Shannon L Carpenter, Joanne Wu, Jonathan C. Roberts, Roshni Kulkarni, Peter A. Kouides, Robert F. Sidonio, Jr., Barbara Konkle, Judith Baker, Megan M. Ullman, Randall Curtis, Nicole Crook, Michael B. Nichol

Blood (2022) 140 (Supplement 1): 5127–5128.

https://doi.org/10.1182/blood-2022-160463

Published: 2022

Journal Articles

Development of a Machine Learning Algorithm for Early Diagnosis of Persons with Von Willebrand Disease Using Real-World Data

Robert F. Sidonio, Jr., Anan Lu, Sarah Hale, Jorge Caicedo, Michael Bullano, Shan Xing

Blood (2022) 140 (Supplement 1): 2713–2714.

https://doi.org/10.1182/blood-2022-163819

Published: 2022

Journal Articles

Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Angela C. Weyand, Martin Chandler, Carol Fedor, Michael Recht, Robert F. Sidonio, Jr.

Blood (2022) 140 (Supplement 1): 5600–5602.

https://doi.org/10.1182/blood-2022-163302

Published: 2022

Journal Articles

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Blood (2022) 140 (Supplement 1): 5597–5599.

https://doi.org/10.1182/blood-2022-156110

Published: 2022

Journal Articles

Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Blood (2022) 140 (Supplement 1): 1413–1415.

https://doi.org/10.1182/blood-2022-156921

Published: 2022

Journal Articles

Reproductive Health Needs in Patients with Bleeding Disorders

Divyaswathi Citla Sridhar, Robert F. Sidonio, Jr., Sanjay Ahuja

Blood (2022) 140 (Supplement 1): 7985–7986.

https://doi.org/10.1182/blood-2022-170085

Published: 2022

Journal Articles

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease

Robert F. Sidonio, Jr., Ana Boban, Leonid Dubey, Adlette Inati, Csongor Kiss, Toshko Lissitchkov, Dzmitry Novik, Elina Peteva, Ali T. Taher, Margarita Arkadevna Timofeeva, Kateryna V. Vilchevska, Vladimir Vdovin, Sylvia Werner, Sigurd Knaub, Claudia Khayat

Blood (2022) 140 (Supplement 1): 8438–8439.

https://doi.org/10.1182/blood-2022-162358

Published: 2022

Journal Articles

Depression and Anxiety in Persons with Von Willebrand Disease

Jonathan C. Roberts, Roshni Kulkarni, Peter A. Kouides, Robert F. Sidonio, Jr., Shannon L Carpenter, Barbara A Konkle, Joanne Wu, Megan M. Ullman, Randall Curtis, Judith Baker, Nicole Crook, Michael B. Nichol

Blood (2021) 138 (Supplement 1): 4052.

https://doi.org/10.1182/blood-2021-151625

Published: 2021

NARROW

RNAing toward a new therapy for hemophilia

Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Heavy Menstrual Bleeding in Females with Von Willebrand Disease

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD

Immunogenicity of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate during the Wil-31 Prophylaxis Study in Patients with Von Willebrand Disease

Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Assessment of Menstrual Health and Bleeding Symptoms in Adolescent Girls and Young Women with Sickle Cell Disease

Performance of the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH) 2.0

Clinical Characteristics Impacting Health-Related Quality of Life in Persons with Von Willebrand Disease

Development of a Machine Learning Algorithm for Early Diagnosis of Persons with Von Willebrand Disease Using Real-World Data

Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Reproductive Health Needs in Patients with Bleeding Disorders

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease

Depression and Anxiety in Persons with Von Willebrand Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only